Agile design and development of a high throughput cobas® SARS-CoV-2 RT-1

PCR diagnostic test 2

- Chitra Manohar¹, Jingtao Sun¹, Peter Schlag¹, Chris Santini¹, Marcel Fontecha¹, Pirmin 3
- Lötscher², Carolin Bier², Kristina Goepfert², Dana Duncan¹, Gene Spier¹, Daniel Jarem¹*, 4
- 5 Dmitriy Kosarikov¹

6

- ¹Roche Molecular Systems, Inc., Pleasanton, United States 7
- 8 ²Roche Diagnostics International AG, Rotkreuz, Switzerland

9

- 10 *Corresponding author
- 11 Global Medical and Scientific Affairs, Roche Molecular Diagnostics
- 12 4300 Hacienda Drive, Pleasanton, CA 94588 USA
- 13 Tel: +1 (908) 524-4705 Email: daniel.jarem@roche.com
- 14
- 15
- Keywords: SARS-CoV-2, COVID-19, pandemic, RT-PCR, diagnostic testing, molecular assay 16
- 17 design
- 18 Running Title: cobas SARS-CoV-2 test development

19 Abstract

- 20 Diagnostic testing is essential for management of the COVID-19 pandemic. An agile assay
- 21 design methodology, optimized for the cobas® 6800/8800 system, was used to develop a dual-
- 22 target, qualitative SARS-CoV-2 RT-PCR test using commercially available reagents and existing
- 23 sample processing and thermocycling profiles. The limit of detection was 0.004 to 0.007
- 24 TCID₅₀/mL for USA-WA1/2020. Assay sensitivity was confirmed for SARS-CoV-2 variants
- 25 Alpha, Beta, Gamma, Delta and Kappa. The coefficients of variation of the cycle threshold
- 26 number (Ct) were between 1.1 and 2.2%. There was no difference in Ct using nasopharyngeal
- 27 compared to oropharyngeal swabs in universal transport medium (UTM). A small increase in Ct
- 28 was observed with specimens collected in cobas® PCR medium compared to UTM. In silico
- analysis indicated that the dual-target test is capable of detecting all >1,800,000 SARS-CoV-2
- 30 sequences in the GISAID database. Our agile assay design approach facilitated rapid
- 31 development and deployment of this SARS-CoV-2 RT-PCR test.

32 **1. Introduction**

| 33 | A novel coronavirus, SARS-CoV-2, is the causative agent of COVID-19, a complex and |
|----|--|
| 34 | potentially lethal human disease (1) that has infected over 200 million individuals worldwide as |
| 35 | of August 2021 (2). The COVID-19 pandemic has been associated with more than four million |
| 36 | deaths (2) and enormous economic impact across the world. SARS-CoV-2 is transmitted person- |
| 37 | to-person via respiratory secretions, causing fever, respiratory symptoms (cough, shortness of |
| 38 | breath), and subsequent immune system dysregulation. The clinical presentation of COVID-19 |
| 39 | can vary from asymptomatic infection to mild illness to fatal disease (3-5). |
| 40 | The Coronaviridae is a family of viruses that cause illness ranging from mild respiratory |
| 41 | infection (human coronaviruses 229E, NL63, HKU1, and OC43) to more severe diseases such as |
| 42 | Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome |
| 43 | (SARS-CoV) (6). SARS-CoV-2 coronavirus belongs to the Sarbecovirus sub-genus, which also |
| 44 | includes SARS-CoV and other betacoronaviridae identified in bats (7, 8). |
| 45 | Diagnostic testing is an essential component of infection prevention, control and disease |
| 46 | management. One of the most sensitive types of diagnostic test currently available is based on |
| 47 | specific detection of viral nucleic acids. One commonly used technology platform for such tests |
| 48 | is real-time reverse transcription (RT)-PCR, which involves binding of primers and probes to |
| 49 | specific regions of the pathogen's genome. Rapid response to the need for testing for novel |
| 50 | pathogens can be achieved by adaptation of existing automated instruments, well-established |
| 51 | generic reagents and production facilities. The cobas® 6800/8800 system (Roche Molecular |
| 52 | Systems) is a widely used platform that supports the detection of many different clinically |
| 53 | important viruses and bacteria using real-time PCR (9). |

3

| 54 | Early in the pandemic only a few SARS-CoV-2 genomic sequences were available in public |
|----|--|
| 55 | databases (e.g. GISAID or NCBI). When the cobas® SARS-CoV-2 test was designed in early |
| 56 | 2020, little was known about what regions of the genome might be subject to sequence variation |
| 57 | and/or recombination. Despite the paucity of knowledge about potential sequence variation, we |
| 58 | designed a single well, dual-target assay to detect SARS-CoV-2-specific sequences using targets |
| 59 | in the non-structural region of the ORF1a/b locus, and a conserved region in the structural |
| 60 | envelope (E)-gene common to all sarbecoviruses, including SARS-CoV-2. The test was designed |
| 61 | to meet the need for high throughput testing on the cobas 6800/8800 system, which performs |
| 62 | fully automated sample preparation, real time RT-PCR reaction setup, target amplification and |
| 63 | detection. |
| 64 | SARS-CoV-2 can evolve in response to external selection pressures. Strong but incomplete |
| 65 | inhibition of replication, which might occur in an infected person with partial immunity, can |
| 66 | result in the selection of SARS-CoV-2 variants that have higher replicative fitness than the wild- |
| 67 | type virus in a population of susceptible hosts. Similarly, if a naturally occurring variant were to |
| 68 | arise with increased ability to spread in an immunologically naïve population, it could out- |
| 69 | compete the wild-type virus in a relatively short period of time. The emergence of several |
| 70 | "variants of concern" (VOC) and "variants of interest" in many different locations of the world |
| 71 | in recent months is therefore not unexpected, and has several important public health and clinical |
| 72 | implications (10-16). Sequence variation in such variants has the potential to interfere with |
| 73 | molecular diagnostic test performance. |

74 **2. Methods**

75 2.1 Viruses

| 76 | An isolate of SARS-CoV-2 from the first patient diagnosed with COVID-19 in the US (USA- |
|----|--|
| 77 | WA1/2020, catalog number NR-52281, lot number 70033175, 2.8×10^5 TCID ₅₀ /mL) (17) was |
| 78 | obtained from BEI Resources (Manassas, VA). Based on information provided in the Certificate |
| 79 | of Analysis from the vendor, one TCID ₅₀ /mL is equal to 7393 genome equivalents (RNA copies) |
| 80 | by droplet digital PCR TM (Bio-Rad [®]). An isolate of SARS-CoV-2 from a German patient |
| 81 | (BetaCoV/Germany/BavPat1/2020, catalog number 026V-03883, 3.2 x 10 ⁶ pfu/mL) was |
| 82 | obtained from the European Virus Archive Global (Marseille, France). All experiments with |
| 83 | replication competent SARS-CoV-2 were performed in a biocontainment level 3 facility in |
| 84 | Switzerland. Virus stocks were diluted in a simulated matrix, consisting of human cells and |
| 85 | mucin in Universal Viral Transport Medium (UTM, Copan Diagnostics, Murrieta, CA; |
| 86 | https://www.copanusa.com/wp-content/uploads/2020/02/UTM-Package-Insert.pdf), that was |
| 87 | shown to be equivalent to natural nasopharyngeal matrix in assay performance (data not shown). |
| 88 | Virus stocks for variants of concern were obtained from BEI Resources (catalog numbers NR- |
| 89 | 54000, NR-54008, NR-54982, NR-55611, NR-55486, NR-55308, NR-55309, NR-55439, NR- |
| 90 | 55469, and NR-55654). For the wild-type strain, genomic RNA was used (NR-52499). Virus |
| 91 | RNA concentration was determined by droplet digital PCR. |
| | |

92 2.2 cobas SARS-CoV-2 assay design

The cobas 6800/8800 platform is an end-to-end system that includes hardware, software,

94 reagents and consumables that performs automated nucleic acid testing. The platform is intended 95 for moderate- to high-throughput laboratories, where a large number of test results are needed 96 within short periods of time. Different tests that are performed on the cobas 6800/8800 system 97 use the same generic reagents and share common sample processing and PCR profiles coupled 98 with target-specific assay oligonucleotides and positive control. Therefore, cobas SARS-CoV-2

5

99 was developed using the automated, well established conditions for the cobas 6800/8800 system, 100 sample preparation workflow and thermal cycling profile, allowing for simultaneous inclusion of 101 other diagnostic tests designed for the cobas 6800/8800 platform (amplification/detection on the 102 same PCR plate). All reagents were developed using synergies whenever possible, such as 103 common raw material, manufacturing and use test (kit release) procedures, controls and PCR 104 reaction master mix formulation. 105 To design primers and probes for the PCR assay, Agile Assay Design (AAD) software (Roche 106 Molecular Systems) was used to select optimal oligonucleotide length and sequence based on the 107 seven available SARS-CoV-2 sequences in the Global Initiative on Sharing All Influenza Data 108 (GISAID, www.gisaid.org) (18). The designs took into consideration key PCR parameters that 109 predict efficient assay performance using Roche master mix and reagents on the cobas 110 6800/8800 system. To evaluate inclusivity, the delay in cycle threshold (dCt) compared to 111 perfectly matching primers was modeled. The algorithm was based on experiments performed 112 with 20 perfectly matched primers at different locations and 268 corresponding, mis-matched 113 primers containing one to six nucleotide mismatches, using both DNA and RNA templates to 114 experimentally measure dCt. The models use thermodynamics parameters (free energies, dG) for 115 DNA:DNA interactions (19). The melting temperatures for probes were calculated using Melting5 software (20) at 100 nM probe concentration, 1.7 mM Mg^{2+} and 50mM Na^+/K^+ . 116

117 2.3 Inclusivity

- 118 Inclusivity analysis was performed using all available SARS-CoV-2 sequences in GISAID as of
- 119 June 15, 2021 (n= 1,874,933). The predicted impact of each variant Target 1 and Target 2 primer
- 120 and probe binding site sequence (six sites) was evaluated using the AAD software and
- 121 quantitated as the predicted increase in Ct or probe melting temperature (Tm).

6

122 2.4 Sensitivity (Limit of Detection)

To determine the limit of detection (LoD), USA-WA1/2020 live virus was serially diluted in simulated clinical matrix. A total of seven concentrations, generated using 3-fold serial dilutions of the stock virus, were tested, with a total of 21 replicates per concentration and an additional 10 replicates of diluent only. LoD was determined by probit analysis based on the titer given by the supplier and dilution factor. The LoD was confirmed using a second virus isolate,

128 BetaCoV/Munich/BavPat1/2020, similarly serially diluted.

129 2.5 Precision

130 Precision was assessed with a panel made using cultured SARS-CoV-2 (USA-WA1/2020, heat-131 inactivated) in simulated clinical matrix in UTM. SARS-CoV-2 virus stock material was serially 132 diluted to generate a panel consisting of three concentration levels (weak, low and moderate 133 positive) corresponding to approximately 0.3x, 1x and 3x the LoD, respectively. The samples 134 were tested over 15 days, three reagent lots, on three instruments and by three operators. Each 135 test day, two runs were performed per lot and per instrument, using three replicates per panel 136 member per run. A total of 90 replicates per concentration level were tested over the course of 137 the study. The 90 replicates were distributed across three reagent lots (30 replicates each) and 138 three cobas® 6800/8800 Systems.

139 2.6 Matrix/Collection media equivalency

140 The relative performance of different specimen types or transport media was evaluated using

141 cultured virus (USA-WA1/2020 strain), spiked into paired specimens from SARS-CoV-2

142 negative individuals with symptoms of an upper respiratory infection collected in 2018 (before

143 the SARS-CoV-2 outbreak) and stored frozen at -80°C. The final virus concentration was

| 144 | approximately 0.054 TCID ₅₀ /mL, or 1.5 times higher than the LoD. The relative performance of |
|-----|---|
| 145 | nasopharyngeal swab (NPS) and oropharyngeal swab (OPS) specimens was compared in |
| 146 | universal viral transport medium (BD, Franklin Lakes, NJ; equivalent to UTM). NPS swabs were |
| 147 | used for the comparison between UTM or the virus-inactivating cobas® PCR Media (CPM; |
| 148 | Roche Molecular Systems) (21). A total of 21 replicates at 0.054 TCID ₅₀ /mL were tested. |
| 149 | Similarly, detection of SARS-CoV-2 RNA in specimens collected using polyester woven or |
| 150 | nylon flocked swabs in UTM or 0.9% saline physiological solution was evaluated using cultured |
| 151 | virus (USA-WA1/2020 strain) spiked into matched nasal swab (NS) specimens from SARS- |
| 152 | CoV-2 negative individuals. Three specimens were self-collected from each of 45 healthy |
| 153 | donors: two using either a woven polyester or nylon flocked swab and placed in UTM, and one |
| 154 | (from the other nostril) using a woven polyester swab placed in 0.9% physiological saline. A |
| 155 | total of 17 replicates at 0.054 TCID ₅₀ /mL were tested. |
| | |

156

157 **3. Results**

158 3.1 Assay Design

At the time when the cobas SARS-CoV-2 test was designed (January 2020), only seven SARS-CoV-2 sequences were available from the Global Initiative on Sharing All Influenza Data (GISAID). To guard against the possibility that viral sequence changes in the target site may negatively impact detection, two complementary strategies were employed. First, a dual target design was chosen, which dramatically increases the likelihood of viral sequence detection and PCR signal preservation from one of the two targets even if the other has sequence variations. Second, selection of target regions where sequences are conserved between virus species (e.g.

| 166 | between SARS-CoV-2 and SARS-CoV) greatly enhances the chance that this sequence will |
|-----|--|
| 167 | remain conserved within species. We selected one target (Target 1) in the ORF1a/b coding |
| 168 | region that is highly specific for SARS-CoV-2. The second target (Target 2) is located in a |
| 169 | region of the E gene that is conserved among sarbecoviruses (Fig. 1). A proprietary software |
| 170 | program, AAD (see Methods), was used to evaluate the seven available SARS-CoV-2 sequences |
| 171 | and over 1000 sequences from other sarbecoviruses, including SARS-CoV, that were available |
| 172 | from NCBI. Target 2 positivity can be interpreted unambiguously given the clinical and |
| 173 | epidemiological context (i.e. with knowledge that SARS-CoV-2 is circulating but SARS-CoV is |
| 174 | not). |

175 3.2 Inclusivity

176 In June 2021, an updated in silico analysis of 1,874,933 SARS-CoV-2 sequences in the GISAID 177 database was performed. Table 1 summarizes the predicted impact of sequence variation at 178 primer or probe binding sites for variants represented in at least 0.02% (403 or more) of all 179 SARS-CoV-2 sequences in the GISAID database (a complete listing of all variants including 180 very infrequent sequences can be found in the Supplemental Data Table S1). A summary of the 181 numbers of individual haplotypes (defined as a specific sequence including the four primer and 182 two probe binding sites) is shown in Table 2. Overall, 98.56% of sequences have no changes in 183 primer or probe binding sites at either target, and 1.4% have only a single change. One of these 184 (variant 13, found in 0.025% of sequences), which has a single change in the probe binding site 185 for Target 2 (Table 1), is predicted to reduce the reactivity of single probes or primers, and has 186 been previously shown to be associated with failure of detection at Target 2 (22). An additional 187 74 (0.004%) sequences, bearing between two and eight nucleotide changes, were observed that 188 are predicted to impact assay performance for target 1 (n=31) or target 2 (n=43; Table 2). No

| 189 | variant reported in the GISAID database had changes in both target regions simultaneously. |
|-----|---|
| 190 | Therefore no impact on cobas SARS-CoV-2 test performance is anticipated, considering all the |
| 191 | sequences available. |
| | |
| 192 | 3.3 Sensitivity (Limit of Detection) |
| 193 | Assay sensitivity was determined by replicate testing of serial dilutions of USA-WA1/2020 |
| 194 | virus. As shown in Table 3, the concentration level with observed test positivity rates \ge 95% were |
| 195 | 0.009 and 0.003 TCID ₅₀ /mL for Target 1 and 2, respectively. The probit model predicted 95% |
| 196 | test positivity rates at virus titers of 0.007 (95% CI: 0.005 – 0.036) and 0.004 (95% CI: 0.002 – |
| 197 | 0.009) TCID ₅₀ /mL for Target 1 and 2, respectively. Based on an estimate of the number of RNA |
| 198 | copies per $TCID_{50}$ in the virus stock used for this experiment, this corresponds to 52 copies/mL |
| 199 | for Target 1 and 30 copies/mL for Target 2. |
| 200 | A second sensitivity study was performed using a different virus isolate |
| 201 | (BetaCoV/Germany/BavPat1/2020) whose concentration is reported in plaque forming units |
| 202 | (pfu) instead of TCID ₅₀ . The concentration levels with observed test positivity rates greater than |
| 203 | or equal to 95% using this isolate were 0.011 pfu/mL for Target 1 and 0.004 pfu/mL for Target 2 |
| 204 | (data not shown). Probit analysis predicted 95% test positivity rates at virus titers of 0.007 |
| 205 | pfu/mL (95% CI: 0.005 – 0.023) for Target 1 and 0.004 pfu/mL (95% CI: 0.002 – 0.009) for |
| 206 | Target 2. |
| 207 | Assay sensitivity for SARS-CoV-2 variants of concern alpha, beta, gamma, and delta (B.1.1.7, |
| 208 | B.1.351, P.1, and B.1.617.2, respectively), variant of interest lambda (C.37), and several variants |
| 209 | under monitoring (some of which were formerly variants of interest) was confirmed by testing 5 |
| 210 | to 8 replicates of three different dilutions of virus stocks for each variant near the LoD |
| 211 | determined above (50 to 250 copies/mL). For Target 1, at the two highest concentrations, all |

| 212 | results were | positive for a | all variants | (Table 4). | . At 50 co | pies/mL for | [•] Target 1 | . 62.5% (| beta) |
|-----|--------------|----------------|--------------|-------------------------|------------|-------------|-----------------------|-----------|-------|
| | | | | (, - , - , - , - , - , | | | | , , - , | |

- 213 87.5% (wild-type, alpha and gamma) or 100% (delta, kappa) of results were positive. At all
- 214 concentrations tested, all results were positive for Target 2.

215 3.4 Precision

- 216 Summary statistics for Ct values for the weak (~0.3x), low (~1.0x), and moderate (~3.0x)
- 217 positive concentration levels by variance component are shown in Table 5. Coefficients of
- 218 variation of less than 2.0% CV were observed for all variables and concentration levels. Slightly
- 219 more variability was observed between reagent lots and in the within-run residual category.
- 220 Precision values of 0.8% CV or less were observed between instruments, day-to-day, and run-to-
- run. Overall, the coefficients of variation ranged from 1.1 to 1.9% for Target 1, and from 1.1 to

222 2.2% for Target 2.

223 3.5 Matrix/Collection media equivalency

224 Nasopharyngeal swab (NPS) and oropharyngeal swab (OPS) specimens are suitable for use in 225 the diagnosis of respiratory virus infections. To demonstrate matrix equivalency, cultured virus 226 (USA-WA1/2020 strain) was spiked into paired OPS or NPS specimens from SARS-CoV-2 227 negative individuals to final concentrations of approximately 0.054 TCID₅₀/mL, or 1.5 times 228 higher than the LoD. The cycle threshold number (Ct, inversely correlated with RNA quantity in 229 the specimen) from replicate tests for each target is shown in Fig. 2. There was no statistically 230 significant difference between mean Ct values in NPS vs OPS for either target (paired t-test P 231 value >0.1).

232 Similar experiments were performed to compare the Ct values in specimens collected in different

types of swabs and collection media. Ct values for specimens diluted in CPM were slightly

higher (difference in mean Ct of 0.4 to 0.7) than in Universal Transport Media (UTM) for both targets (paired t-test *P* value ≤ 0.002 ; Fig. 3A). Specimens collected using nylon flocked swabs in UTM yielded a minimal increase in mean Ct vs. polyester woven swabs in the same medium (difference 0.6 Ct, paired t-test *P* value 0.0065), while polyester woven swabs in saline yielded similar Ct values compared to the same type of swab in UTM (paired t-test *P* value >0.4; Fig. 3B).

240 **4. Discussion**

241 Deployment of new diagnostic tests for emerging pathogens in a timely manner is an integral 242 part of the public health response to pandemics, such as the one caused by infection with SARS-243 CoV-2. Several different factors can be leveraged to speed development and deployment of 244 novel diagnostic assays at the start of a pandemic or any emerging infectious disease. When tests 245 for new targets can be deployed using existing infrastructure central testing laboratories can 246 capitalize on already deployed instruments and trained personnel. The cobas 6800/8800 platform 247 represents such an opportunity, since real-time PCR primers and probes can be designed to work 248 in the context of existing, well-characterized assay chemistry and conditions. The AAD software 249 for primer/probe design is an effective tool that facilitates rapid assay development for new 250 pathogens. In addition, when reference materials are available for preparation of contrived 251 specimens in a variety of authentic and simulated clinical matrices, initial performance 252 evaluations required for emergency use authorization can be completed quickly. The 253 convergence of these features enabled the rapid development of this diagnostic test, which was 254 the first such test granted emergency use authorization in the US in early 2020. 255 The paucity of sequence data at the early stages of an outbreak is a significant challenge for 256 molecular test development (23, 24). The cobas SARS-CoV-2 test primers and probes were

12

257 designed at a time when only seven genomic sequences were publicly available. However, 258 sequence conservation may be predicted by considering data from related viruses for which more 259 sequences have been characterized. A region of conserved sequence across different virus 260 species is also likely to remain conserved within a species in the future. 261 Our approach included two different sets of primers and probes, one of which (Target 1) is 262 specific for ORF1a/1b of SARS-CoV-2, while the other (Target 2) is intended to react with E-263 gene sequences of SARS-CoV-2, SARS-CoV, and other sarbecoviruses that infect bats. The 264 genes in which the targets should be located were not pre-determined, but instead the AAD 265 approach identified sites anywhere in the genome predicted to provide the best performance and 266 desired level of sequence conservation. While Target 2 reactivity is expected for both SARS-267 CoV and SARS-CoV-2, virus positivity can be unambiguously established with knowledge of 268 extant virus and disease prevalence, and in combination with the SARS-CoV-2 specific Target 1 269 result. Importantly, the use of two targets enables test accuracy even in the presence of sequence 270 variation in one of the two target sequences. This has been demonstrated to occur in at least one 271 case (22).

272 The limit of detection of the cobas SARS-CoV-2 test was determined to be between 0.004 and 273 $0.007 \text{ TCID}_{50}/\text{mL}$ or between 30 and 52 copies/mL for the particular virus stock used here. It 274 should be noted that the relationship between TCID₅₀ (or plaque forming units) and number of 275 RNA copies may differ between virus preparations; this may explain small differences in LoD 276 reported in RNA copies/mL elsewhere (25). A lower LoD for the E-gene target compared to 277 other targets has been reported previously (26), which is consistent with our results. We noted 278 that at low virus input levels, Target 1 positivity is impacted more than Target 2, in spite of 279 higher Ct values for Target 2.

| 280 | Previous evaluations have provided conflicting results regarding the relative sensitivity of |
|-----|---|
| 281 | SARS-CoV-2 RT-PCR assays using NPS, OPS or other specimen types (27-34). Our results |
| 282 | support the use of either NPS or OPS as the specimen type, since there was no difference in the |
| 283 | ability to detect SARS-CoV-2 RNA spiked into either specimen at low levels. While NPS is |
| 284 | viewed as the gold standard for many respiratory pathogens, OPS are easier to obtain and less |
| 285 | intrusive for the patient. These findings should be confirmed with specimens from infected |
| 286 | individuals in the clinic. |
| 287 | In the early phases of the COVID-19 pandemic, many clinicians experienced a shortage of |
| 288 | recommended sample collection materials including media for specimen storage and shipping. |
| 289 | Our data indicate equivalent sensitivity of the cobas SARS-CoV-2 test when specimens are |
| 290 | stored in UTM, CPM or saline, as long as specimens are refrigerated (2-8 °C) and stored for 6 |
| 291 | days or less. CPM has the added advantage of inactivating the infectivity of SARS-CoV-2, thus |
| 292 | improving biosafety for specimen handling in the laboratory (21). |
| 293 | Several independent studies have reported on the performance of the cobas SARS-CoV-2 test, in |
| 294 | comparison with laboratory-developed tests (LDTs) or other commercial assays. Generally, |
| 295 | overall percent agreement values range from 95 to 99% (25, 26, 35-37), with more discordance |
| 296 | observed in specimens with low viral loads (35, 36, 38). |
| 297 | In conclusion, the cobas SARS-CoV-2 is a robust, sensitive and specific test for qualitative |
| 298 | diagnosis of infection by SARS-CoV-2 that can be performed using equipment and infrastructure |
| 299 | already widely available in clinical reference laboratories globally. The rapid development and |
| 300 | deployment of this test was made possible by the application of the AAD approach and early |
| 301 | availability of sequence information and reference reagents. |
| | |

302

303 Acknowledgements

- 304 This publication was supported by the European Virus Archive GLOBAL (EVA-GLOBAL)
- 305 project that has received funding from the European Union's Horizon 2020 research and
- 306 innovation programme under grant agreement No 871029. Manuscript preparation services were
- 307 provided by Data First Consulting (Sebastopol, CA).

308

309 Conflict of Interest

- 310 All authors except C.B., K.G. and P.L. are employees and stockholders of Roche Molecular
- 311 Systems, Inc. C.B., K.G. and P.L. are employees of Roche Diagnostics International AG.

References

 Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus I, Research T. 2020. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 382:727-733.

 Dong E, Du H, Gardner L. 2020. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 20:533-534.

3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for C. 2020. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 382:1708-1720.

4. Onder G, Rezza G, Brusaferro S. 2020. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 323:1775-1776.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y,
 Zhao Y, Li Y, Wang X, Peng Z. 2020. Clinical Characteristics of 138 Hospitalized Patients
 With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 323:1061-1069.

Bchetnia M, Girard C, Duchaine C, Laprise C. 2020. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status.
J Infect Public Health 13:1601-1610.

Boni MF, Lemey P, Jiang X, Lam TT, Perry BW, Castoe TA, Rambaut A, Robertson DL.
 2020. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the
 COVID-19 pandemic. Nat Microbiol 5:1408-1417.

8. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N, Bi Y, Ma

X, Zhan F, Wang L, Hu T, Zhou H, Hu Z, Zhou W, Zhao L, Chen J, Meng Y, Wang J, Lin Y,

Yuan J, Xie Z, Ma J, Liu WJ, Wang D, Xu W, Holmes EC, Gao GF, Wu G, Chen W, Shi W,

Tan W. 2020. Genomic characterisation and epidemiology of 2019 novel coronavirus:

implications for virus origins and receptor binding. Lancet 395:565-574.

9. Cobb B, Simon CO, Stramer SL, Body B, Mitchell PS, Reisch N, Stevens W, Carmona S, Katz L, Will S, Liesenfeld O. 2017. The cobas(R) 6800/8800 System: a new era of automation in molecular diagnostics. Expert Rev Mol Diagn 17:167-180.

10. Lauring AS, Hodcroft EB. 2021. Genetic Variants of SARS-CoV-2-What Do They Mean? JAMA 325:529-531.

11. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D, Pillay S, San EJ, Msomi N, Mlisana K, von Gottberg A, Walaza S, Allam M, Ismail A, Mohale T, Glass AJ, Engelbrecht S, Van Zyl G, Preiser W, Petruccione F, Sigal A, Hardie D, Marais G, Hsiao M, Korsman S, Davies MA, Tyers L, Mudau I, York D, Maslo C, Goedhals D, Abrahams S, Laguda-Akingba O, Alisoltani-Dehkordi A, Godzik A, Wibmer CK, Sewell BT, Lourenco J, Alcantara LCJ, Kosakovsky Pond SL, Weaver S, Martin D, Lessells RJ, Bhiman JN, Williamson C, de Oliveira T. 2021. Emergence of a SARS-CoV-2 variant of concern with mutations in spike glycoprotein. Nature.

Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, Connor T, Peacock T,
 Robertson DL, Volz E, COVID-19 Genomics Consortium UK Preliminary genomic

characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations. [Online.] <u>https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563</u>. Accessed March 17, 2021.

13. Eurosurveillance editorial team. 2021. Updated rapid risk assessment from ECDC on the risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA - first update. Euro Surveill 26.

 Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A, Slayton RB, Tong S, Silk BJ, Armstrong GL, Biggerstaff M, Dugan VG. 2021. Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020-January 12, 2021. MMWR Morb Mortal Wkly Rep 70:95-99.

15. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, Ludden C, Reeve R, Rambaut A, Consortium C-GU, Peacock SJ, Robertson DL. 2021. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 19:409-424.

Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L, Geneva Centre forEmerging Viral D. 2021. Novel SARS-CoV-2 variants: the pandemics within the pandemic.Clin Microbiol Infect.

17. Harcourt J, Tamin A, Lu X, Kamili S, Sakthivel SK, Murray J, Queen K, Tao Y, Paden CR, Zhang J, Li Y, Uehara A, Wang H, Goldsmith C, Bullock HA, Wang L, Whitaker B, Lynch B, Gautam R, Schindewolf C, Lokugamage KG, Scharton D, Plante JA, Mirchandani D, Widen SG, Narayanan K, Makino S, Ksiazek TG, Plante KS, Weaver SC, Lindstrom S, Tong S, Menachery VD, Thornburg NJ. 2020. Severe Acute Respiratory Syndrome Coronavirus 2 from Patient with Coronavirus Disease, United States. Emerg Infect Dis 26:1266-1273.

18. Shu Y, McCauley J. 2017. GISAID: Global initiative on sharing all influenza data - from vision to reality. Euro Surveill 22:30494.

 SantaLucia J, Jr., Hicks D. 2004. The thermodynamics of DNA structural motifs. Annu Rev Biophys Biomol Struct 33:415-440.

20. Dumousseau M, Rodriguez N, Juty N, Le Novere N. 2012. MELTING, a flexible platform to predict the melting temperatures of nucleic acids. BMC Bioinformatics 13:101.

21. Norz D, Frontzek A, Eigner U, Oestereich L, Wichmann D, Kluge S, Fischer N,

Aepfelbacher M, Pfefferle S, Lutgehetmann M. 2020. Pushing beyond specifications:

Evaluation of linearity and clinical performance of the cobas 6800/8800 SARS-CoV-2 RT-PCR

assay for reliable quantification in blood and other materials outside recommendations. J Clin Virol 132:104650.

22. Artesi M, Bontems S, Gobbels P, Franckh M, Maes P, Boreux R, Meex C, Melin P,

Hayette MP, Bours V, Durkin K. 2020. A Recurrent Mutation at Position 26340 of SARS-CoV-

2 Is Associated with Failure of the E Gene Quantitative Reverse Transcription-PCR Utilized in a Commercial Dual-Target Diagnostic Assay. J Clin Microbiol 58.

23. Damond F, Roquebert B, Benard A, Collin G, Miceli M, Yeni P, Brun-Vezinet F, Descamps D. 2007. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Microbiol 45:3436-3438.

24. Damond F, Avettand-Fenoel V, Collin G, Roquebert B, Plantier JC, Ganon A, Sizmann D, Babiel R, Glaubitz J, Chaix ML, Brun-Vezinet F, Descamps D, Rouzioux C. 2010.
Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification. J Clin Microbiol 48:1413-1416.

25. Dust K, Hedley A, Nichol K, Stein D, Adam H, Karlowsky JA, Bullard J, Van Caeseele P, Alexander DC. 2020. Comparison of commercial assays and laboratory developed tests for detection of SARS-CoV-2. J Virol Methods 285:113970.

26. Pujadas E, Ibeh N, Hernandez MM, Waluszko A, Sidorenko T, Flores V, Shiffrin B, Chiu N, Young-Francois A, Nowak MD, Paniz-Mondolfi AE, Sordillo EM, Cordon-Cardo C, Houldsworth J, Gitman MR. 2020. Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time

RT-PCR test. J Med Virol 92:1695-1698.

Wang H, Liu Q, Hu J, Zhou M, Yu MQ, Li KY, Xu D, Xiao Y, Yang JY, Lu YJ, WangF, Yin P, Xu SY. 2020. Nasopharyngeal Swabs Are More Sensitive Than Oropharyngeal Swabsfor COVID-19 Diagnosis and Monitoring the SARS-CoV-2 Load. Front Med (Lausanne) 7:334.

28. Wang X, Tan L, Wang X, Liu W, Lu Y, Cheng L, Sun Z. 2020. Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously. Int J Infect Dis 94:107-109.

Rogers AA, Baumann RE, Borillo GA, Kagan RM, Batterman HJ, Galdzicka MM,
 Marlowe EM. 2020. Evaluation of Transport Media and Specimen Transport Conditions for the
 Detection of SARS-CoV-2 by Use of Real-Time Reverse Transcription-PCR. J Clin Microbiol
 58.

30. Patel MR, Carroll D, Ussery E, Whitham H, Elkins CA, Noble-Wang J, Rasheed JK, Lu X, Lindstrom S, Bowen V, Waller J, Armstrong G, Gerber S, Brooks JT. 2020. Performance of oropharyngeal swab testing compared to nasopharyngeal swab testing for diagnosis of COVID-19 -United States, January-February 2020. Clin Infect Dis.

31. Mawaddah A, Gendeh HS, Lum SG, Marina MB. 2020. Upper respiratory tract sampling in COVID-19. Malays J Pathol 42:23-35.

32. Liu M, Li Q, Zhou J, Ai W, Zheng X, Zeng J, Liu Y, Xiang X, Guo R, Li X, Wu X, Xu H, Jiang L, Zhang H, Chen J, Tian L, Luo J, Luo C. 2020. Value of swab types and collection time on SARS-COV-2 detection using RT-PCR assay. J Virol Methods 286:113974.

33. Calame A, Mazza L, Renzoni A, Kaiser L, Schibler M. 2020. Sensitivity of nasopharyngeal, oropharyngeal, and nasal wash specimens for SARS-CoV-2 detection in the setting of sampling device shortage. Eur J Clin Microbiol Infect Dis.

34. Bwire GM, Majigo MV, Njiro BJ, Mawazo A. 2020. Detection profile of SARS-CoV-2 using RT-PCR in different types of clinical specimens: A systematic review and meta-analysis. J Med Virol.

35. Craney AR, Velu PD, Satlin MJ, Fauntleroy KA, Callan K, Robertson A, La Spina M,

Lei B, Chen A, Alston T, Rozman A, Loda M, Rennert H, Cushing M, Westblade LF. 2020.

Comparison of Two High-Throughput Reverse Transcription-PCR Systems for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2. J Clin Microbiol 58.

Moran A, Beavis KG, Matushek SM, Ciaglia C, Francois N, Tesic V, Love N. 2020.
 Detection of SARS-CoV-2 by Use of the Cepheid Xpert Xpress SARS-CoV-2 and Roche cobas
 SARS-CoV-2 Assays. J Clin Microbiol 58.

37. Poljak M, Korva M, Knap Gasper N, Fujs Komlos K, Sagadin M, Ursic T, Avsic Zupanc
T, Petrovec M. 2020. Clinical Evaluation of the cobas SARS-CoV-2 Test and a Diagnostic
Platform Switch during 48 Hours in the Midst of the COVID-19 Pandemic. J Clin Microbiol 58.

38. Lowe CF, Matic N, Ritchie G, Lawson T, Stefanovic A, Champagne S, Leung V,

Romney MG. 2020. Detection of low levels of SARS-CoV-2 RNA from nasopharyngeal swabs using three commercial molecular assays. J Clin Virol 128:104387.

Figure Legends

Figure 1. SARS-CoV-2 genome diagram and location of cobas assay target regions. ORF: open reading frame; S: spike; E: envelope; M: matrix; N: nucleocapsid. Forward and reverse primers are represented by arrows, and probes by black rectangles, for Target 1 (ORF1a/b) and 2 (E gene).

Figure 2. Specimen type equivalency. Individual results are plotted for each specimen type and target; horizontal bars represent the mean and standard deviation (SD) for each group. NPS: nasopharyngeal swab; OPS: oropharyngeal swab. Target 1 (filled circles) and Target 2 (open circles) are shown separately.

Figure 3. Specimen collection matrix equivalency. **A**: CPM vs. UTM. **B**. flocked or woven swabs in UTM and woven swabs in saline. Individual results are plotted for each matrix and target; horizontal bars represent the mean and standard deviation (SD) for each group. CPM: cobas PCR medium; UTM: universal transport medium. Target 1 (filled circles) and Target 2 (open circles) are shown separately.

| | | | Target 1 (number of differences) | | | Target 2 (number of differences) | | | | | |
|--------------|-----------|------------|----------------------------------|-------|---------|----------------------------------|---------|-------|---------|----------------------|------------------|
| | Frequency | Percentage | Forward | Probe | Reverse | Predicted Impact* | Forward | Probe | Reverse | Predicted Impact* | Assay Overall |
| Reference | 1,847,992 | 98.56% | 0 | 0 | 0 | No | 0 | 0 | 0 | No | ? |
| Variant 1 | 3895 | 0.21% | 0 | 1 | 0 | No | 0 | 0 | 0 | No | ? |
| Variant 2 | 3717 | 0.20% | 0 | 0 | 0 | No | 1 | 0 | 0 | No | ? |
| Variant 3 | 2395 | 0.13% | 0 | 1 | 0 | No | 0 | 0 | 0 | No | ? |
| Variant 4 | 1383 | 0.074% | 0 | 0 | 1 | No | 0 | 0 | 0 | No | ? |
| Variant 5 | 1185 | 0.063% | 0 | 1 | 0 | No | 0 | 0 | 0 | No | ? |
| Variant 6 | 790 | 0.042% | 0 | 0 | 0 | No | 1 | 0 | 0 | No | ? |
| Variant 7 | 771 | 0.041% | 1 | 0 | 0 | No | 0 | 0 | 0 | No | ? |
| Variant 8 | 747 | 0.040% | 0 | 0 | 0 | No | 0 | 0 | 1 | No | ? |
| Variant 9 | 606 | 0.032% | 0 | 1 | 0 | No | 0 | 0 | 0 | No | ? |
| Variant 10 | 529 | 0.028% | 0 | 1 | 0 | No | 0 | 0 | 0 | No | ? |
| Variant 11 | 496 | 0.027% | 0 | 0 | 1 | No | 0 | 0 | 0 | No | ? |
| Variant 12 | 479 | 0.026% | 0 | 1 | 0 | No | 0 | 0 | 0 | No | ? |
| Variant 13** | 462 | 0.025% | 0 | 0 | 0 | No | 0 | 1 | 0 | Yes | ? |
| Variant 14 | 431 | 0.023% | 0 | 0 | 0 | No | 1 | 0 | 0 | No | ? |
| Variant 15 | 422 | 0.023% | 0 | 0 | 0 | No | 1 | 0 | 0 | No | ? |
| Variant 16 | 403 | 0.022% | 0 | 0 | 1 | No | 0 | 0 | 0 | No | ? |

Table 1 Analysis of cobas SARS-CoV-2 primer and probe binding site sequence variation.

* "Predicted Impact" indicates the predicted combined impact of the sequence changes in the primers or probe binding site on assay signal. No: predicted Ct increase less than 5 cycles, probe $Tm > 65^{\circ}C$; Yes: predicted to potentially increase Ct >5 cycles, probe $Tm < 65^{\circ}C$, or the reported C-T mismatch near the probe 5' end (22); the majority of cases with any predicted increase in Ct were 1-2 cycles. Variants present in more than 0.02% of sequences in GISAID as of June 15, 2021 are shown. For a complete listing of less

common variants, see Supplemental Material Table S1. ** This variant confirmed experimentally to reduce Target 2 (but not Target 1) reactivity (22).

| Target | N differences in haplotype | N different haplotypes | Frequency | Count with impact | Frequency with impact | Total % | % with impact |
|----------|-------------------------------|---------------------------|-----------|----------------------|--------------------------|---------|---------------|
| 1 | 0 | 238 | 1,857,440 | 0 | 0 | 99.07% | 0% |
| | 1 | 235 | 17,139 | 0 | 0 | 0.91% | 0.0000% |
| | 2 | 42 | 339 | 9 | 21 | 0.018% | 0.0011% |
| | 3 | 10 | 10 | 7 | 7 | 0.0005% | 0.0004% |
| | 4 | 2 | 2 | 1 | 1 | 0.0001% | 0.0001% |
| | 5 | 1 | 1 | 0 | 0 | 0.0001% | 0% |
| | 6 | 1 | 1 | 1 | 1 | 0.0001% | 0.0001% |
| | 7 | 1 | 1 | 1 | 1 | 0.0001% | 0.0001% |
| 2 | 0 | 243 | 1,865,363 | 0 | 0 | 99.49% | 0% |
| | 1 | 227 | 9,465 | 5 | 467 | 0.50% | 0.0249% |
| | 2 | 34 | 65 | 3 | 4 | 0.0035% | 0.0002% |
| | 3 | 4 | 4 | 3 | 3 | 0.0002% | 0.0002% |
| | 4 | 3 | 3 | 3 | 3 | 0.0002% | 0.0002% |
| | 5 | 3 | 3 | 3 | 3 | 0.0002% | 0.0002% |
| | 6 | 6 | 17 | 6 | 17 | 0.0009% | 0.0009% |
| | 7 | 6 | 9 | 6 | 9 | 0.0005% | 0.0005% |
| | 8 | 2 | 2 | 2 | 2 | 0.0001% | 0.0001% |
| | 9 | 2 | 2 | 2 | 2 | 0.0001% | 0.0001% |
| combined | 0 | 1 | 1,847,992 | 0 | 0 | 98.56% | 0% |
| | 1 | 365 | 26,367 | 0 | 0 | 1.41% | 0% |
| | 2 | 121 | 515 | 0 | 0 | 0.027% | 0% |
| | 3 | 16 | 18 | 0 | 0 | 0.0010% | 0% |
| | 4 | 5 | 5 | 0 | 0 | 0.0003% | 0% |
| | 5 | 4 | 4 | 0 | 0 | 0.0002% | 0% |
| | 6 | 7 | 18 | 0 | 0 | 0.0010% | 0% |
| | 7 | 6 | 7 | 0 | 0 | 0.0004% | 0% |
| | 8 | 3 | 5 | 0 | 0 | 0.0003% | 0% |
| | 9 | 2 | 2 | 0 | 0 | 0.0001% | 0% |

 Table 2. Summary of Assay Inclusivity.

Table 3 Limit of detection

| | RNA | | Test positivity (%)† | | Mean Ct‡ | |
|---|-------------------------------|------------------------|----------------------|----------|----------|----------|
| Concentration (TCID ₅₀ /mL) | concentration (copies/mL)* | Total valid results | Target 1 | Target 2 | Target 1 | Target 2 |
| 0.084 | 621 | 21 | 100 | 100 | 31.0 | 33.0 |
| 0.028 | 207 | 21 | 100 | 100 | 31.8 | 34.1 |
| 0.009 | 67 | 21 | 100 | 100 | 32.7 | 35.2 |
| 0.003 | 22 | 21 | 38.1 | 100 | 33.5 | 36.4 |
| 0.001 | 7.4 | 21 | 0 | 52.4 | n/a | 37.9 |
| 0.0003 | 2.2 | 21 | 0 | 14.3 | n/a | 37.2 |
| 0.0001 | 0.7 | 21 | 0 | 9.5 | n/a | 38.5 |
| 0 (blank) | 0 | 10 | 0 | 0 | n/a | n/a |

* Conversion from TCID₅₀/mL to RNA copies/mL based on information provided in the Certificate of Analysis from the vendor: one

 $TCID_{50}/mL$ is equal to 7393 genome equivalents (RNA copies) by droplet digital PCR

† All replicates where Target 1 was positive were also positive for Target 2.

‡ Calculations only include positive results.

| Variant | Concentration (copies/mL) | N positive/N tested (Target 1) | N positive/N tested (Target 2) |
|-------------------|------------------------------|-----------------------------------|-----------------------------------|
| Wildtype | 250 | 8/8 | <u> </u> |
| 51 | 100 | 8/8 | 8/8 |
| | 50 | 7/8 | 8/8 |
| Alpha (B.1.1.7) | 250 | 8/8 | 8/8 |
| • | 100 | 8/8 | 8/8 |
| | 50 | 7/8 | 8/8 |
| Beta (B.1.351) | 250 | 8/8 | 8/8 |
| | 100 | 8/8 | 8/8 |
| | 50 | 5/8 | 8/8 |
| Gamma (P.1) | 250 | 8/8 | 8/8 |
| | 100 | 8/8 | 8/8 |
| | 50 | 7/8 | 8/8 |
| Delta (B.1.617.2) | 250 | 5/5 | 5/5 |
| | 100 | 5/5 | 5/5 |
| | 50 | 5/5 | 5/5 |
| Kappa (B.1.617.1) | 250 | 5/5 | 5/5 |
| | 100 | 5/5 | 5/5 |
| | 50 | 5/5 | 5/5 |
| Epsilon (B.1.427) | 250 | 5/5 | 5/5 |
| • | 100 | 5/5 | 5/5 |
| | 50 | 5/5 | 5/5 |
| Epsilon (B.1.429) | 250 | 5/5 | 5/5 |
| | 100 | 5/5 | 5/5 |
| | 50 | 5/5 | 5/5 |
| Zeta (P.2) | 250 | 5/5 | 5/5 |
| | 100 | 5/5 | 5/5 |
| | 50 | 5/5 | 5/5 |
| Lambda (C.37) | 250 | 5/5 | 5/5 |
| . , | 100 | 5/5 | 5/5 |
| | 50 | 5/5 | 5/5 |
| R.1 | 250 | 5/5 | 5/5 |
| | 100 | 5/5 | 5/5 |
| | 50 | 5/5 | 5/5 |

Table 4 Detection of variants of concern, variants of interest and variants under monitoring

Table 5 Assay precision

| | | | | | Instrument to- Instrument | | Lot-to-Lot | | Day-to-Day | | Run-to-Run | | Within-Run (Residual) | | Total | |
|---|----------|------------------|----------|---------|---------------------------------|-----|------------|-----|------------|-----|------------|-----|--------------------------|-----|-------|-----|
| _ | Target | Level (x LoD) | Hit rate | Mean Ct | SD | CV% | SD | CV% | SD | CV% | SD | CV% | SD | CV% | SD | CV% |
| | Target 1 | ~0.3x | 10.0% | 32.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 1.4 | 0.5 | 1.4 |
| | | ~1.0x | 91.1% | 32.1 | 0.0 | 0.0 | 0.2 | 0.6 | 0.1 | 0.3 | 0.0 | 0.0 | 0.6 | 1.8 | 0.6 | 1.9 |
| | | ~3.0x | 100.0% | 31.2 | 0.0 | 0.0 | 0.2 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.9 | 0.4 | 1.1 |
| | Target 2 | ~0.3x | 34.4% | 35.4 | 0.0 | 0.0 | 0.5 | 1.3 | 0.3 | 0.8 | 0.1 | 0.2 | 0.5 | 1.5 | 0.8 | 2.2 |
| | | ~1.0x | 93.3% | 34.2 | 0.0 | 0.0 | 0.1 | 0.3 | 0.2 | 0.6 | 0.0 | 0.0 | 0.7 | 2.0 | 0.7 | 2.2 |
| | | ~3.0x | 100.0% | 32.9 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | 1.1 | 0.4 | 1.1 |

Figures





Figure 2. Specimen type equivalency.





Figure 3. Specimen collection matrix equivalency.